MAPK1 and cardiac hypertrophy: This critical role of the ERK pathway in the development of cardiac hypertrophy (in response to endothelin-1) was also confirmed by the in vitro abrogation of cardiomyocyte hypertrophy in the presence of the pharmacological inhibitor of ERKs [63, 64].